Changes observed in radionuclide bone scans during and after teriparatide treatment for osteoporosis
| Autor: | Amelia E. B. Moore, Xiaohai Wan, Glen M. Blake, Valerie A Ruff, Asad E. Rana, Kathleen A. Taylor, Ignac Fogelman |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Time Factors Bone density Osteoporosis Visual changes Technetium Tc 99m Medronate Bone scans Bone and Bones Bone remodeling Bone remodelling Bone Density Teriparatide medicine Humans Radiology Nuclear Medicine and imaging Whole Body Imaging Radionuclide Imaging 99mTc-MDP bone scan Osteoporosis Postmenopausal Aged Postmenopausal women business.industry General Medicine Middle Aged medicine.disease Radiology Nuclear Medicine and imaging Orthopedic surgery Original Article Female Radiology Bone Remodeling business Nuclear medicine Bone turnover markers medicine.drug |
| Zdroj: | European Journal of Nuclear Medicine and Molecular Imaging |
| ISSN: | 1619-7089 1619-7070 |
| Popis: | Purpose Visual changes on radionuclide bone scans have been reported with teriparatide treatment. To assess this, serial studies were evaluated and quantified in ten postmenopausal women with osteoporosis treated with teriparatide (20 μg/day subcutaneous) who had 99mTc-methylene diphosphonate (MDP) bone scans (baseline, 3 and 18 months, then after 6 months off therapy). Methods Women were injected with 600 MBq 99mTc-MDP, and diagnostic bone scan images were assessed at 3.5 h. Additional whole-body scans (10 min, 1, 2, 3 and 4 h) were analysed for 99mTc-MDP skeletal plasma clearance (Kbone). Regional Kbone differences were obtained for the whole skeleton and six regions (calvarium, mandible, spine, pelvis, upper and lower extremities). Bone turnover markers (BTM) were also measured. Results Most subjects showed visual changes on 3- and 18-month bone scan images that disappeared after 6 months off therapy. Enhanced uptake was seen predominantly in the calvarium and lower extremities. Whole skeleton Kbone displayed a median increase of 22% (3 months, p = 0.004) and 34% (18 months, p = 0.002) decreasing to 0.7% (6 months off therapy). Calvarium Kbone changes were three times larger than other sites. After 6 months off therapy, all Kbone and BTM values returned towards baseline. Conclusion The increased 99mTc-MDP skeletal uptake with teriparatide indicated increased bone formation which was supported by BTM increases. After 6 months off therapy, metabolic activity diminished towards baseline. The modulation of 99mTc-MDP skeletal uptake during treatment was the result of teriparatide’s metabolic activity. These findings may aid the radiological evaluation of similar teriparatide patients having radionuclide bone scans. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink